Cancer Family
Squamous Cell Neoplasm
CI-CAN-00000359Explore in graph →
Non-malignant1,024 active trials9 approved drugs78 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000359Explore in graph →
Clinical trials
3,210 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07244978 | Neoadjuvant Ivonescimab(AK112) Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 49 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT07545083 | Neoadjuvant Becotatug Vedotin Plus Pucotenlimab in Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma (OSCC) | not yet recruiting | Phase 2 | 26 | Shanghai Zhongshan HospitalOTHER | 0 |
| Apr 22, 2026 |
| clinicaltrials |
| NCT07361133 | Cyclophosphamide and Etoposide as a Metronomic Therapy in Advanced Head and Neck Squamous Cell Cancer | not yet recruiting | Phase 2 | 120 | National Cancer Institute, EgyptOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT07529873 | Phase II Study of Ficerafusp Alfa in Combination With Nivolumab in Patients With Platinum-refractory Head and Neck Squamous Cell Carcinoma(N'FORCE) | not yet recruiting | Phase 2 | 131 | Groupe Oncologie Radiotherapie Tete et CouOTHER | 0 | Apr 14, 2026 | clinicaltrials |
| NCT07514767 | Evaluation of the Efficacy and Safety of Nivolumab Neoadjuvant Treatment of Patients With Locally Advanced Oral Squamous Cell Carcinoma(NOCANO) | not yet recruiting | Phase 2 | 60 | Prof. Lars Olaf CardellOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT07505186 | Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 45 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT06418724 | Neoadjuvant PD-1 Inhibitor and EGFR Inhibitor in Locally Advanced Cutaneous Squamous Cell Carcinoma(NEOPECS) | not yet recruiting | Phase 2 | 27 | Melanoma and Skin Cancer Trials LimitedOTHER | 0 | Mar 27, 2026 | clinicaltrials |
| NCT07491783 | Nano-Carbon Iron Suspension Injection Combined With Radiotherapy for Solid Tumors Phase II Clinical Trial | not yet recruiting | Phase 2 | 52 | Sichuan Enray Pharmaceutical Sciences CompanyOTHER | 1 | Mar 24, 2026 | clinicaltrials |
| NCT06876038 | Low-cost Screening and Image-guided Photodynamic Therapy (PDT) of Premalignant and Malignant Oral Lesions | not yet recruiting | Phase 2 | 65 | University of Massachusetts, BostonOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT07469241 | Study of MRI Guided Personal Chemoradiotherapy and Immunotherapy for Limited Advanced Esophageal Squamous Caicinoma.(FUTURE-3) | not yet recruiting | Phase 2 | 50 | Fudan UniversityOTHER | 0 | Mar 13, 2026 | clinicaltrials |
| NCT07428148 | Lattice-Based Radiotherapy and Chemoimmunotherapy for Oropharyngeal Squamous Cell Carcinoma | not yet recruiting | Phase 1 / Phase 2 | 60 | NYU Langone HealthOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT07403435 | Short-course Radiotherapy Combined With Serplulimab and Chemotherapy as Neoadjuvant Treatment for Resectable ESCC | not yet recruiting | Phase 2 | 22 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT07400094 | Neoadjuvant Chemoimmunotherapy (Camrelizumab + Paclitaxel + Carboplatin) for Resectable HNSCC(NeoCamre-HN) | not yet recruiting | Phase 2 | 50 | National Medical Research Radiological Centre of the Ministry of Health of RussiaOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT07393477 | Neoadjuvant Becotatug Vedotin Plus Pucotenlimab and Cisplatin for Locally Advanced Head and Neck Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 30 | Sir Run Run Shaw HospitalOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT07394244 | Pucotenlimab Combined With Becotatug Vedotin in Advanced Cutaneous Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 38 | Fudan UniversityOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT07379424 | A Single-arm, Phase II, Multi-center Clinical Trial of Sintilimab During the Perioperative Period in Patients With Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 37 | chen chao ProfessorOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT07376876 | Indocyanine Green-guided Omental Shield Anastomosis for Cervical Esophagogastric Anastomosis in Minimally Invasive McKeown Esophagectomy | not yet recruiting | Phase 2 | 73 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT07354984 | A Single-Arm Phase II Clinical Study of Docetaxel Combined With Nimotuzumab and Pucotenlimab as Second-Line and Beyond Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma(PIONEER-HN) | not yet recruiting | Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT07346196 | A Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck | not yet recruiting | Phase 2 | 90 | University of ChicagoOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT07346807 | Lingual Nerve Disruption to Augment Neoadjuvant Chemoimmunotherapy in Locally Advanced Tongue Cancer | not yet recruiting | Phase 2 | 69 | Shanghai Zhongshan HospitalOTHER | 1 | Jan 16, 2026 | clinicaltrials |
| NCT07310771 | Sintilimab-Nimotuzumab Induction Followed by Chemoradiation-Nimotuzumab in LA-HNSCC: Single-Arm Phase II | not yet recruiting | Phase 2 | 23 | Fujian Cancer HospitalOTHER_GOV | 0 | Dec 30, 2025 | clinicaltrials |
| NCT07272291 | A Phase II Study of Toripalimab Plus Chemotherapy and Low-Dose Radiotherapy for Neoadjuvant Therapy-Refractory Esophageal Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 48 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Dec 9, 2025 | clinicaltrials |
| NCT07251062 | A Study of SYS6010, Enlonstobart, and Chemotherapy for First-Line Treatment of Esophageal Squamous Cell Carcinoma. | not yet recruiting | Phase 2 / Phase 3 | 737 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 0 | Nov 26, 2025 | clinicaltrials |
| NCT06989671 | SYS6002 Plus JMT101 and Enlonstobart Injection in Participants With HNSCC | not yet recruiting | Phase 2 | 430 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 0 | Aug 27, 2025 | clinicaltrials |
| NCT07135804 | Iparomlimab and Tuvonralimab Injection for Untreated Locally Advanced Nasopharyngeal Carcinoma | not yet recruiting | Phase 2 | 45 | Second Affiliated Hospital of Nanchang UniversityOTHER | 0 | Aug 22, 2025 | clinicaltrials |
| NCT07137858 | Adebrelimab Combined With Carboplatin and Albumin-bound Taxanol in the Treatment of Resectable Locally Advanced Oral Squamous Cell Carcinoma Cardiac, Randomized, Phase II Exploratory Study | not yet recruiting | Phase 2 | 70 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 0 | Aug 22, 2025 | clinicaltrials |
| NCT07128693 | A Single-center, Multicohort, Phase II Clinical Study Evaluating the Combination Therapy of Sacituzumab Tirumotecan in Patients With Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 60 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 0 | Aug 19, 2025 | clinicaltrials |
| NCT07112833 | A Phase II Clinical Study of Induction Adebrelimab Combined With Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC) | not yet recruiting | Phase 2 | 36 | Hebei Medical University Fourth HospitalOTHER | 1 | Aug 8, 2025 | clinicaltrials |
| NCT07090707 | PD-1 Inhibitor Therapy Versus Radiotherapy in MPR Patients With Locally Advanced HNSCC After Neoadjuvant Immunochemotherapy (HNC-SYSU-006) | not yet recruiting | Phase 2 | 50 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jul 29, 2025 | clinicaltrials |
| NCT07079410 | Neoadjuvant and Adjuvant Sintilimab Plus Cetuximab in Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma(OSCC) | not yet recruiting | Phase 2 | 50 | Shanghai Zhongshan HospitalOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT07049185 | QL1706 Plus Celecoxib in Advanced Esophageal Squamous Cell Carcinoma(QICE-ESCC) | not yet recruiting | Phase 2 | 35 | Peking University Cancer Hospital & InstituteOTHER | 0 | Jul 3, 2025 | clinicaltrials |
| NCT07009925 | Phase II Study of Platinum (Cisplatin/Carboplatin)and Polymeric Micelles Paclitaxel(Pm-Pac) With Ivonescimab in First Line Metastatic Squamous NSCLC. | not yet recruiting | Phase 2 | 38 | Jiangsu Cancer Institute & HospitalOTHER | 0 | Jun 8, 2025 | clinicaltrials |
| NCT06861894 | Active Surveillance After Neoadjuvant Adebrelimab Combined With Chemoradiotherapy for Resectable ESCC | not yet recruiting | Phase 2 | 164 | Zhigang LiOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT06861712 | Chemoimmunotherapy With or Without SBRT Before Surgery for Locally Advanced Oral and Oropharyngeal Cancer | not yet recruiting | Phase 2 | 50 | Sun Yat-sen UniversityOTHER | 1 | Apr 25, 2025 | clinicaltrials |
| NCT06482307 | Molecular Imaging of DNA Damage Response by [18F]-Olaparib PET([18F]-olaparib) | not yet recruiting | Phase 1 / Phase 2 | 10 | University Medical Center GroningenOTHER | 1 | Apr 18, 2025 | clinicaltrials |
| NCT06875791 | Safety and Efficacy Trial of TV5M01 for Radiation-Induced Mucositis in Head and Neck Cancer Patients.(TEMOR) | not yet recruiting | Phase 1 / Phase 2 | 40 | Fundacion Clinica Valle del LiliOTHER | 1 | Apr 1, 2025 | clinicaltrials |
| NCT06903871 | Toripalimab Adjuvant Therapy in Subjects With Resected Esophageal Squamous Cell Carcinoma Who Achieved Pathological Complete Response (pCR) | not yet recruiting | Phase 2 | 190 | Hebei Medical University Fourth HospitalOTHER | 1 | Apr 1, 2025 | clinicaltrials |
| NCT06895369 | The Efficacy and Safety of Pucotenlimab Combined With TP Chemotherapy as Neoadjuvant Therapy for Locally Advanced HNSCC | not yet recruiting | Phase 2 | 30 | Sir Run Run Shaw HospitalOTHER | 1 | Mar 26, 2025 | clinicaltrials |
| NCT05835804 | Intratumoral Gemcitabine, Paclitaxel, Carboplatine and Intravenous Nivolumab for Locally Recurrence of Head and Neck Cancers(NIVOCHIMLOC) | not yet recruiting | Phase 2 | 39 | Centre Hospitalier Universitaire, AmiensOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT06861777 | Total Neoadjuvant Therapy Combined With Adebrelimab in Locally Advanced Resectable ESCC | not yet recruiting | Phase 2 / Phase 3 | 474 | YIN LIOTHER | 1 | Mar 11, 2025 | clinicaltrials |
| NCT06852456 | QL1706 in Combination With Neoadjuvant Chemotherapy Versus Neoadjuvant Chemotherapy for Locally Advanced, Resectable Esophageal Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 30 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Feb 28, 2025 | clinicaltrials |
| NCT06814067 | Phase II Multi-centered Study of Perioperative Ivonescimab Versus Pembrolizumab Combined with Standard of Care (SOC) in Patients with Resectable, Locally Advanced Head and Neck Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 80 | Fudan UniversityOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT06759155 | Phase II Clinical Trial of De-Intensified Therapy in Human Papilloma Virus (HPV) Associated Oropharyngeal Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 20 | University of Vermont Medical CenterOTHER | 0 | Jan 6, 2025 | clinicaltrials |
| NCT06746961 | Efficacy and Safety of QL1706 Plus Lenvatinib As 2nd Line Theapy in Patients with Metastatic Esophageal Carcinoma After Disease Progression on ICIs Therapy | not yet recruiting | Phase 1 / Phase 2 | 49 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 0 | Dec 24, 2024 | clinicaltrials |
| NCT06728618 | Preoperative Tislelizumab -Cetuximab - Chemotherapy Followed by Salvage Surgery and Adjuvant Tislelizumab -Cetuximab for Resectable, Locally Recurrent Oral and Oropharyngeal Squamous Cell Carcinoma(OSCC) | not yet recruiting | Phase 2 | 28 | Shanghai Zhongshan HospitalOTHER | 1 | Dec 11, 2024 | clinicaltrials |
| NCT06719479 | A Clinical Trial to Evaluate Effect of IAE0972 Combined with Chemotherapy for R/M HNSCC or NPC(Note: It is Currently Phase II.). | not yet recruiting | Phase 2 / Phase 3 | 60 | SUNHO(China)BioPharmaceutical CO., Ltd.INDUSTRY | 0 | Dec 5, 2024 | clinicaltrials |
| NCT06714266 | Trilaciclib in Preventing Hematopoietic Suppression in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 30 | Shandong Cancer Hospital and InstituteOTHER | 0 | Dec 3, 2024 | clinicaltrials |
| NCT06703047 | Tislelizumab Combined with Chemotherapy and All Trans Retinoic Acid for Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 180 | Fudan UniversityOTHER | 0 | Nov 25, 2024 | clinicaltrials |
| NCT06699498 | Neoadjuvant Therapy of Targeted Immunotherapy Combined With Chemotherapy for Locally Advanced HNSCC | not yet recruiting | Phase 2 | 45 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Nov 21, 2024 | clinicaltrials |
| NCT06694350 | Pembrolizumab in Combination with Flutamide Treatment for Recurrence / Metastasis HNSCC | not yet recruiting | Phase 2 | 54 | Zhejiang Provincial People's HospitalOTHER | 0 | Nov 19, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Apr 24, 2026source: clinicaltrials